Targeting VPS4A/B Synthetic Lethality: A New Tool for ATPase Drug Discovery

Selective inhibition of VPS4A and/or VPS4B represents a promising synthetic lethality approach in oncology. However, achieving specificity without affecting related ATPases remains a major challenge.

Join us for this webinar to explore how BellBrook Labs has developed a robust high-throughput assay for VPS4A/VPS4B ATPase activity—enabling efficient screening and structure-activity relationship (SAR) optimization for potential anticancer compounds. Using our sensitive Transcreener® ADP² Assay with a far-red fluorescence readout, we’ve created a powerful new tool to accelerate the discovery of selective VPS4 inhibitors.

In this webinar, you’ll learn:

• Why VPS4A and VPS4B are compelling oncology targets – and how their synthetic lethality opens new therapeutic avenues
• How our HTS-compatible assay was developed using purified enzymes and optimized for initial velocity detection
• How we validated the assay with Z’ > 0.7 and identified two potent hits—BVT948 and polygodial—from a known bioactives library
• Strategies for minimizing off-target effects when working with ATPase inhibitors
• How this assay platform supports HTS, SAR, and hit-to-lead development for drug discovery teams

Whether you’re working in oncology, drug discovery, or assay development, this webinar will give you practical insights and tools to support your research.

View the previously recorded webinar now and learn how to screen smarter.